Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Starting HIV treatment early and then interrupting is no better than delaying it

A French study that looked at the total amount of time since infection that people with HIV have spent with a detectable viral load has found that,

Published
22 January 2015
By
Gus Cairns
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
Study uncovers new ground about when to start HIV therapy

A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

Published
13 January 2015
From
CATIE
Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

Published
12 January 2015
From
The Institute for Quality and Efficiency in Health Care
First Year After HIV Infection Is Key Window for Treatment Start

Waiting to start HIV treatment until 12 months after the estimated date of seroconversion decreases the likelihood of restoring the immune system.

Published
07 January 2015
From
AIDSMeds
Elite controllers may pay a high price for their low viral load

About one in 200 people with HIV maintains an undetectable viral load and high CD4 counts without having to take antiretroviral therapy (ART). These so-called ‘elite controllers’

Published
07 January 2015
By
Gus Cairns
How San Francisco Is Getting to Zero On HIV

San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.

Published
11 December 2014
From
Huffington Post
Starting HIV Meds Within a Year of Infection Helps Restore CD4s

Beginning treatment for HIV within a year of infection improves the likelihood of returning an individual’s CD4 count to a normal level.

Published
03 December 2014
From
AIDSMeds
CDC Analyzes Impediments to Viral Suppression in People With HIV

The CDC has reframed the HIV treatment cascade figures to highlight the various reasons why only 30 percent of Americans have a fully suppressed virus.

Published
03 December 2014
From
POZ
Does ‘treat’ always follow ‘test’? Why some people do not want HIV treatment

In South Africa, only one third of individuals living with HIV are actually on treatment. Treatment refusal has been identified as a phenomenon among people who are asymptomatic, however, factors driving refusal remain poorly understood.

Published
01 December 2014
From
UNAIDS Science Now
← First12345...65Next →

Filter by country